More clinical research focusing on NF1-mutated melanoma, one of the four molecular subgroups classified by The Cancer Genome Atlas, is expected since no efficient targeted therapy has so far been available, unlike for the BRAF-mutated subgroup (BRAF/MEK inhibitors) or NRAS-mutated subgroup (MEK inhibitors clinical trials). This evidence concerns the gene BRAF and melanoma.